Medicare’s Part D out-of-pocket cap will rise to $2,400 in 2027, up from $2,100 in 2026. This $300 increase may outweigh the benefit of lower negotiated prices on certain drugs, including Ozempic, which is used to treat type 2 diabetes. By the numbers, patients who reach the cap in both years will pay $300 more in 2027 despite the lower prices.
The bottom line is that the higher cap only affects patients whose spending reaches the limit, such as those taking several costly drugs. Investors will note that the Part D out-of-pocket cap applies to covered drugs, and once the spending reaches $2,400, beneficiaries enter catastrophic coverage and pay no more for covered Part D drugs for the rest of the year.
Medicare Part D Parameters For 2027
The Centers for Medicare & Medicaid Services set the 2027 Part D parameters, including a $2,400 out-of-pocket cap and a $700 maximum deductible. The figure that matters for patients taking costly oral cancer drugs is the cap, as they may reach it early in the year and then pay nothing more for covered Part D drugs until January 2028. The negotiated price sets what Medicare drug plans pay for each drug, and what beneficiaries pay depends on three parts of their plan: deductible, coinsurance, and flat copays.
Impact On Patients And Open Enrollment
Medicare open enrollment runs through December 7, giving beneficiaries time to compare options on the Medicare Plan Finder. Patients taking costly drugs, such as targeted therapies and oral chemotherapy, should review their plans, as the $2,400 cap is the clearest guide to next year’s costs. The Medicare Prescription Payment Plan allows beneficiaries to pay their Part D drug costs in monthly bills, which does not lower their total but can make the expense more manageable.
For patients relying on maintenance drugs like Ozempic, the key is to understand how the new prices and cap affect their annual spending. The negotiated prices will take effect on January 1, 2027, and will apply to 15 drugs, including Ozempic, Rybelsus, and Wegovy. Beneficiaries should review their plans and consider switching to a different plan if it would reduce their out-of-pocket costs. The next scheduled date is December 7, 2026, when open enrollment closes.
Sources
- He Will Take Ozempic for Type 2 Diabetes in 2027, When Medicare's Negotiated Price Takes Effect. His Part D Out-of-Pocket Cap Will Rise From $2,100 to $2,400
- He Will Take Ozempic for Type 2 Diabetes in 2027, When Medicare’s Negotiated Price Takes Effect. His Part D Out-of-Pocket Cap Will Rise From $2,100 to $2,400 – AOL
- He Will Take Ozempic for Type 2 Diabetes in 2027, When Medicare’s Negotiated Price Takes Effect. His Part D Out-of-Pocket Cap Will Rise From $2,100 to $2,400 – AOL
- Medicare Part D 2027: What a $2,400 Cap Means for Cancer Drugs | CURE
- Medicare open enrollment runs through Dec. 7 as Part D costs change
Photo: Joseph Sintum / Unsplash (Unsplash License)
